Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Identification of a Conserved Temporal Molecular Response Signature to CDK4/6 Inhibition Through Multi-Omics Integration Across Cancer Cell Lines.

Created on 14 Nov 2026

Authors

Anna C Hogger, Ting Hong, Klaus Mantwill, Nadine Gaisa, Jürgen E Gschwend, Roman Nawroth

Published in

International journal of molecular sciences. Volume 27. Issue 19. Sep 24, 2026. Epub Sep 24, 2026.

Abstract

Treatment of metastatic breast cancer with CDK4/6 inhibitors in combination with hormone ablation is the current first-line standard of care for this indication, and the therapeutic activity of these inhibitors has been demonstrated in various tumor entities. However, the efficacy of CDK4/6 inhibitor monotherapy is limited and requires combination with suitable additional inhibitors. Delineating the molecular pathways underlying treatment response may provide a rationale for personalized combination therapies that target deregulated pathways upstream of the core signature of response. We applied a comprehensive cross-omics approach to identify a conserved molecular response to CDK4/6 inhibition. Integration of transcriptomic, proteomic, and functional genomic data across multiple cancer models enabled us to refine a previously proposed multi-step model of response to the CDK4/6 inhibitor palbociclib. Initiation of cell-cycle arrest and inhibition of DNA replication is followed by activation of signaling events that suppress mitotic transcriptional programs. The identified panel of highly conserved candidate biomarkers warrants future experimental and clinical validation.

PMID:
42883756
Bibliographic data and abstract were imported from PubMed on 14 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 14
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement